(Wednesday, 25 September 2024, Amsterdam, Netherlands) A pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity
Critically, GIP receptor activation in adipose (fat) tissue appears to enhance fat mobilization and energy expenditure beyond what GLP-1 can do alone which helps explain tirzepatides superior weight loss outcomes in clinical trials
Switching discussions
Yes, it can, and it happens because of the same reason the medicine works so well for weight loss
Your provider will help you understand how each medication functions so that your plan fits your health goals, medical history, and personal comfort level